Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NV701 vs Vuity for Pupil Size in Presbyopia
NCT06783686Phase 1Completed
- Sponsor
- Novus Vision
- Start
- Jan 2025
- Primary completion
- Apr 2025
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of NV701 in presbyopia (2 arms), sponsored by Novus Vision. Primary endpoint: Change in pupil size over 8 hours. Started Jan 2025; status: completed.
02
Drugs
NV701
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT06783686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783686.